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Our hypothesis is that changes in gene and protein expression are crucial to the development of late-onset Alzheimer’s disease.
Previously we examined how DNA alleles control downstream expression of RNA transcripts and how those relationships are
changed in late-onset Alzheimer’s disease. We have now examined how proteins are incorporated into networks in two separate
series and evaluated our outputs in two different cell lines. Our pipeline included the following steps: (i) predicting expression
quantitative trait loci; (ii) determining differential expression; (iii) analysing networks of transcript and peptide relationships; and
(iv) validating effects in two separate cell lines. We performed all our analysis in two separate brain series to validate effects. Our
two series included 345 samples in the ﬁrst set (177 controls, 168 cases; age range 65–105; 58% female; KRONOSII cohort) and
409 samples in the replicate set (153 controls, 141 cases, 115 mild cognitive impairment; age range 66–107; 63% female; RUSH
cohort). Our top target is heat shock protein family A member 2 (HSPA2), which was identiﬁed as a key driver in our two
datasets. HSPA2 was validated in two cell lines, with overexpression driving further elevation of amyloid-b40 and amyloid-b42
levels in APP mutant cells, as well as signiﬁcant elevation of microtubule associated protein tau and phosphorylated-tau in a
modiﬁed neuroglioma line. This work further demonstrates that studying changes in gene and protein expression is crucial to
understanding late onset disease and further nominates HSPA2 as a speciﬁc key regulator of late-onset Alzheimer’s disease
processes.
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Introduction
Along with other groups, we have proposed that systems
approaches to ﬁnding novel genes involved in disease path-
ways can be more powerful than DNA-only approaches
(Myers, 2012, 2013, 2014). We have previously examined
genotype–transcript relationships via expression quantita-
tive trait loci analysis and constructed regulatory networks
(Myers et al., 2007a; Webster et al., 2009; Zhang et al.,
2013). In this report, we extend the original work using
two independent datasets and integrated mass spectrometry
proteomics (Piehowski et al., 2013). In addition, by experi-
mentally validating the top replicated key drivers using two
independent cell-based models, we directly tested predic-
tions from the network models regarding their impact on
late-onset Alzheimer’s disease pathology.
Proteins are the primary effectors of human phenotypes,
so it is crucial to understand protein expression in the con-
text of gene variation and transcript expression. Prior work
to integrate proteomic data into the analysis of biological
networks has been successfully performed in humans
(Garge et al., 2010; Portelli et al., 2014; Stark et al.,
2014), yeast (Foss et al., 2007; Wu et al., 2008) and ro-
dents (Fei et al., 2011; Ghazalpour et al., 2011). Most of
the human data to date have been collected from lympho-
blasts (Garge et al., 2010; Stark et al., 2014), which are
highly subject to de novo mutation. Such cell-based systems
are not ideal for constructing models of human disease,
especially as many targets found in lymphoblast screens
do not replicate in brain tissues (Hong et al., 2008).
In this report, we present the ﬁrst replication ‘omics screen
that includes DNA variation, RNA expression, and tandem
mass spectrometry proteome proﬁles in two series of human
brains, 50% of which are pathologically conﬁrmed late-
onset Alzheimer’s disease tissues and one of which includes
samples collected worldwide (Supplementary Fig. 1). These
two sets were analysed independently to determine relation-
ships between DNA, RNA and protein. Our pipeline (Fig. 1)
involved testing for single effects, such as differential expres-
sion of both transcripts and peptides as well as expression
quantitative trait loci to examine single relationships be-
tween transcript and peptide abundances and allele content.
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Network analyses were used to capture more complex rela-
tionships between groups of data. We performed both ana-
lysis mapping how expression proﬁles were related between
multiple transcript and peptide targets (co-expression net-
work analysis) as well as mapping the causal structures
within the data (causal network analysis). Causal network
analysis is an expansion of co-expression analysis, in that the
relationships between transcript and or peptide targets are
given an order and direction in these predictions. For ex-
ample, in co-expression analysis, relationships are mapped
such that target A contacts targets B and C. In causal ana-
lysis, target A could be mapped upstream of targets B and C
and could contact B before C. For the causal network ana-
lyses, we used a novel expansion of standard Bayesian net-
work approaches, which allows for the analysis of opposite
causality (i.e. both negative and positive correlations). This
causal predictive network type of analysis is more compre-
hensive than testing single transcripts or proteins against
single nucleotide polymorphisms (SNPs), which is the
common procedure in expression quantitative trait loci stu-
dies and is the procedure carried out in many prior reports
including the human proteome (Garge et al., 2010; Stark
et al., 2014). Additionally, the multiple layers of regulation
that can occur between DNA and protein make the protein-
SNP relationships more complex and multivariate network
approaches are capable of capturing relationships among all
targets. Our ﬁnal step is to narrow down our list of targets
from the causal predictions by performing a key driver ana-
lysis. Key driver analysis involves looking for targets
(formally, nodes within the causal structure) that have a
higher number of connections than would be expected
given a background.
While it was important to identify targets in brain, the
causal consequences of changing levels of targets are stat-
istically inferred; therefore, validating the predictions is crit-
ical. We used several different cell lines to validate targets
outside the context of human brain tissue, measuring levels
of amyloid-b40, amyloid-b42, total tau and phosphorylated
(p)-tau to examine the downstream consequences of chan-
ging predicted target transcript and protein expression. Our
hypothesis is that novel ﬁndings will be acting on a back-
ground of pathological expression of both amyloid-b and
tau, i.e. our effects would act as modiﬁers of known
pathology.
We present an integrated, multi-level analysis of how the
analysis of DNA, RNA, and protein data can facilitate the
study of the relationships among genes and proteins and
their impact on the human brain in the context of late-
onset Alzheimer’s disease. These targets are vetted through
a multi-pass validation procedure including multiple types
of analysis, replication across multiple datasets, in silico
predictions and in vitro validations.
Materials and methods
All procedures are extensively detailed in the Supplementary
material.
Figure 1 Analysis pipeline. A summary of the steps that were taken on the processed data is shown. Round rectangles indicate input data,
green round rectangles indicate input data from external sources, and orange squares indicate processes and outputs from those processes. Steps
are numbered on the figure. See main text for further detail. BN = Bayesaian network; DBs = databases; DE = differential expression;
eQTL = expression quantitative trait loci; GO = Gene Ontology database; mSig = Molecular Signatures Database; WGCNA = weighted corre-
lation network analysis.
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Samples
KRONOSII is a subset of data already presented (Corneveaux
et al., 2010) and contains samples from Alzheimer’s Disease
Research Center-funded US brain banks as well as six
European and British brain banks. KRONOSII is a conveni-
ence cohort with low secondary pathology (i.e. Lewy body
disease) and high pathology load in the late-onset
Alzheimer’s disease affected samples and low pathology load
for controls. The second set (RUSH) includes subjects from
two large, prospectively followed cohorts maintained by inves-
tigators at Rush University Medical Center in Chicago, IL: The
Religious Orders Study and the Memory and Aging Project.
The RUSH set is an epidemiologically based cohort with a
greater mix of pathologies and pathological staging. There
are 168 late onset Alzheimer’s disease-affected samples and
177 unaffected samples with all datasets collected for the
KRONOSII cohort. From the RUSH cohort 141 late-onset
Alzheimer’s disease affected samples and 153 unaffected sam-
ples with all datasets were collected. The average age for the
KRONOSII cohort is 81, with 59% female subjects. The aver-
age age of the RUSH cohort is 88 and 63% of the subjects are
female. Tissue sections were taken from frontal (82% of the
sample) and temporal (18% of the sample) cortical regions.
Data collection
Genomic DNA samples were analysed on the Genome-Wide
Human SNP 6.0 Array (Affymetrix) according to the manufac-
turer’s protocols. Birdsuite (Korn et al., 2008) was used to call
SNP genotypes from CEL ﬁles. The DNA quality control pipe-
line was similar to that described in Anderson et al. (2010).
cRNA was hybridized to Illumina HumanRefseq-HT-12 v2
Expression BeadChip. Expression proﬁles were extracted, back-
ground was subtracted and missing bead types imputed using
the BeadStudio software. Normalization for the RNA proﬁles
was performed using lumi (Du et al., 2008) and limma
(Ritchie et al., 2015). Sample data were adjusted for several
biological covariates (gender, age at death and cortical region)
and several methodological covariates (institute source of
sample, post-mortem interval, detection and hybridization
date). Tandem mass spectrometry analysis was performed
using an Exactive Orbitrap mass spectrometer (Thermo
Scientiﬁc) outﬁtted with a custom electrospray ionization (ESI)
interface. Identiﬁcation and quantiﬁcation of peptides was per-
formed using the accurate mass and time tag approach (Zimmer
et al., 2006). Decon2LS was used for peak-picking and for
determining isotopic distributions and charge states (Jaitly
et al., 2009). De-isotoped spectral information was loaded into
VIPER to ﬁnd and match features to the peptide identiﬁcations
in the accurate mass and time tag database (Monroe et al.,
2007). Relative peptide quantitation was based on ratios
between intensities of natural 16O isotope containing peptides
and reference peptides labeled with stable 18O isotope at the
carbonyl group at the C-terminus of the peptide.
Data analysis
Our data analysis pipeline is shown in Fig. 1. This was a
multi-pass selection procedure to both uncover late-onset
Alzheimer’s disease risk targets and place them in the context
of upstream regulation (allelic information) and downstream
outputs (transcripts and peptides). Our goal was to identify a
minimal set of high-conﬁdence targets for validation. Our
pipeline was performed in KRONOSII and RUSH separately
after normalization to ensure independent replication.
Differential expression
Differential expression analysis was performed using limma
(Ritchie et al., 2015) comparing late-onset Alzheimer’s disease
and pathologically conﬁrmed controls. Each dataset
(KRONOSII, RUSH) was run independently. Multiple testing
adjustment was performed using Benjamini-Hochberg correc-
tion [5% false discovery rate (FDR)]. Results were used to
deﬁne seeding sets for downstream analysis.
Expression quantitative trait loci
MatrixeQTL (Shabalin, 2012) was used to predict allele-tran-
script relationships. Each dataset (KRONOSII, RUSH) was run
independently. Permutations were used to correct for both the
dependence between individual tests and for multiple testing
(Supplementary material).
Network analysis
We carried out network analyses that took as input genomic,
transcriptomic and proteomic proﬁles from the two datasets
(KRONOSII and RUSH), in addition to external data derived
from the literature, pathway databases (Molecular Signatures
Database, Gene Ontology Database), and the Roadmap initia-
tives (Roadmap Epigenomics Consortium et al., 2015). Our
goal was to produce an output list of the main biological pro-
cesses that are dysregulated in late-onset Alzheimer’s disease, as
well as a small list of the top key drivers impacting late-onset
Alzheimer’s disease associated processes. KRONOSII and RUSH
were treated as independent datasets and the effects were com-
pared across sets to determine replicated targets. Our pipeline
included the following procedures (Fig. 1, Steps 3–6, dark
orange squares): (i) constructing co-expression networks to iden-
tify sets of co-regulated genes associated with late-onset
Alzheimer’s disease pathology (Step 3) and determining path-
ways enriched in each network module (Step 4b); (ii) determin-
ing seeding gene sets associated with late-onset Alzheimer’s
disease pathology (Step 4a, Module Selection and Module
Enrichment); (iii) building multiscale causal predictive networks
(Step 5); and (iv) determining the key drivers that modulate
states of the causal predictive network subnetworks (Step 6).
Co-expression networks
We constructed co-expression networks separately in controls
and late-onset Alzheimer’s disease samples. Additionally, co-ex-
pression networks were constructed separately in KRONOSII
and RUSH. Single-scale networks consisted of transcripts only
or proteins only. Multi-scale networks included transcripts plus
proteins, with reduction of the transcript set to modules that
were most enriched for differentially expressed genes. Our tran-
script co-expression networks consisted of all 15297 transcripts
(Supplementary material: Ancillary Dataset 4, KRONOSII
Transcript co-expression networks; and Ancillary Dataset 5,
RUSH Transcript co-expression networks), the protein-only co-
expression networks consisted of 1931 peptides (Supplementary
material: Ancillary Dataset 6, KRONOSII Peptide co-expression
networks; and Ancillary Dataset 7, RUSH Peptide co-expression
networks), and the multiscale co-expression networks consisted
of 15297 transcripts and 1931 peptides (Supplementary material:
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Ancillary Dataset 8, KRONOSII multiscale co-expression net-
works; and Ancillary Dataset 9, RUSH multiscale co-expression
networks). Prior to building our networks, we hypothesized that
using peptide information may be more informative than using
protein aggregate information in the context of networks (i.e.
collapsing all peptides mapping to a single gene to one target).
This hypothesis was based on data indicating that the four pep-
tides mapping to MAPT showed quite different signals, with
two peptides differentially expressed and two peptides not-
signiﬁcantly different. As network analysis is based on correlative
structures and not genomic locations, we hypothesized that pep-
tides that had functions implicated in late-onset Alzheimer’s
disease pathogenesis (i.e. the two differentially expressed MAPT
peptides), might cluster separately from peptides that were
unchanged in late-onset Alzheimer’s disease (i.e. the two non-
signiﬁcant MAPT peptides). To test this, we constructed a co-
expression network with only peptide data. For both KRONOSII
and RUSH, peptides of the same protein did not always cluster in
the same modules (Fig. 3A–D), supporting that using individual
peptide level data may capture more diverse biology, since indi-
vidual peptides may track completely different transcript modiﬁ-
cations that may not have correlated levels of expression due
to alterations in function. Examining the speciﬁc test case of
MAPT peptides, in both KRONOSII and RUSH [which were
quality controlled together, but predictions were run independ-
ently (Supplementary material)], the two differentially expressed
peptides clustered together, and one of the non-signiﬁcant pep-
tides was consistently in another module. The last peptide
(MAPT_HLSNVSSTGSIDMVDSPQLATLADEVSASLAK) was
somewhat noisy, mapping outside of the differential expres-
sion peptide module in RUSH, but within that module in
KRONOSII.
Causal predictive networks
While co-expression networks allow for descriptive character-
izations of gene-protein relationships, causal relationships pre-
diction is necessary for ordering of the network data into a
hierarchy of relationships that in turn enables key driver ana-
lyses. While co-expression networks reﬂect only associative re-
lationships, Bayesian networks infer directed edges that
represent the direction of information ﬂow. Bayesian network
analysis can capture non-linear and combinatorial interactions.
One limitation to standard Bayesian network analysis is that
sometimes substructures within a Bayesian network are contra-
dictory, which results in many directed edges having low con-
ﬁdence. To address this inherent limitation, we developed a
novel causal predictive network approach, integrating a top-
down Bayesian network approach with bottom-up causal in-
ference that takes into account known causal relationships,
which breaks the symmetry among contradictory causal struc-
tures and thus leads to higher conﬁdence in edge directions.
The complexity of network building is a function of the
number of nodes considered and sample size. We used all pep-
tides in the network constructions; however, given the large
number of probes used to query gene expression levels, we
reduced the number of transcript probes to use in the causal
predictive network reconstruction without losing important
late-onset Alzheimer’s disease gene and pathway information.
We built gene-only co-expression networks and identiﬁed
those modules enriched for differentially expressed genes,
and then restricted causal predictive network construction to
this subset of coherent late-onset Alzheimer’s disease focused
gene sets.
We focused our search on the identiﬁcation of key drivers of
network states associated with late-onset Alzheimer’s disease,
and thus used only late-onset Alzheimer’s disease datasets. The
seeding gene sets for both the KRONOSII and RUSH late-
onset Alzheimer’s disease datasets included modules enriched
for differentially expressed transcript targets; therefore, path-
ways of relevance for late-onset Alzheimer’s disease pathology
were selected. We expanded these sets to include more than
just differentially-expressed transcripts by including priors
from a literature-based brain-speciﬁc network. Given the
modest number of peptides measured, all peptides were used
in the network models. Transcript data were reduced to the
most crucial targets (Module Selection) and then expanded by
including additional targets from the same pathways in curated
databases (Module Enrichment). To ensure robust replication,
KRONOSII and RUSH were pipelined as separate sets.
Key driver analysis
After the causal predictive network analysis was performed,
the resulting predictive network models were examined using
a key driver analysis algorithm. Key drivers are targets that
have a signiﬁcant impact on the regulatory states of other
targets. Key drivers were predicted separately for KRONOSII
and RUSH and overlaps determined. The late-onset
Alzheimer’s disease-associated subnetworks to which key
driver analysis was applied were generated by projecting mul-
tiple different datasets onto the networks. First, we projected
the module enrichment set only including differentially ex-
pressed transcripts from KRONOSII or RUSH. Second, we
projected each module in its entirety including transcripts
from KRONOSII or RUSH. Next, we projected the full differ-
entially expressed transcript set from either KRONOSII or
RUSH. For the peptide data, we ﬁrst projected sets including
both transcripts and peptides, performing the analysis separ-
ately on KRONOSII and RUSH. Finally, the entire peptide set
was projected onto the transcript-peptide causal network, per-
forming the analysis separately on KRONOSII and RUSH.
Data validation
While the identiﬁcation of key drivers using the above ap-
proach is completely data driven, the inferences are statistical
in nature and our results need to be veriﬁed experimentally.
We used two different human cell lines which model the ca-
nonical amyloid-b and tau late-onset Alzheimer’s disease path-
ways to validate hits outside the context of human brain
tissue. Amyloid-b accumulation in plaques is thought to be
the primary event in Alzheimer’s disease pathogenesis (Hardy
and Selkoe, 2002) and tau accumulation is one of the hallmark
early features of Alzheimer’s disease (Serrano-Pozo et al.,
2011); therefore, our hypothesis was that targets of interest
should affect amyloid-b and tau levels further in the context
of ongoing pathology. It is crucial for these studies to prove
speciﬁcity of our effects to the speciﬁc single targets involved in
late-onset Alzheimer’s disease. While we and others have
found general pathways such as inﬂammation that are
involved in the pathogenic late-onset Alzheimer’s disease pro-
cess (Zhang et al., 2013); those pathways have also been
found in several other diseases (Miller and Raison, 2016;
Miller et al., 2017); and thus, while interesting, are
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inappropriate for validating that our targets are speciﬁc to late-
onset Alzheimer’s disease declines and not neurodegeneration
in general.
We used two different lines. First, all targets were transduced
into the APPswe HEK293 line. This is a human embryonal
kidney cell line expressing amyloid-b complementary DNA
bearing a double mutation [K595N and M596L; HEK293sw;
gift from D. Selkoe, Boston, MA (Citron et al., 1992)]. These
cells produce 89-fold more APP mRNA than cells without the
mutations (t-test P-value = 0.006). Levels of total tau protein
and hyperphosphorylated tau were assessed in an H4 neuro-
glioma cell line engineered to overexpress four repeat tau [H4–
4R0N, gift from T. Dunkley, Phoenix, AZ (Azorsa et al.,
2010)]. The H4–4R0N line produces 5-fold more tau protein
than cells without the construct. Using these lines demon-
strated both speciﬁcity of effects to late-onset Alzheimer’s dis-
ease, as amyloid-b processing in particular is a hallmark sign
of disease, and replicated causality, since targets were modelled
individually via overexpression or knockdown. Showing effects
of the expression of single targets on amyloid-b and tau in
external cell systems alleviates any concerns that computation-
ally predicted brain tissue effects were merely the result of
tissue degradation or age-related degeneration in general.
Data availability
All data are available through links at the Laboratory of
Functional Genomics website (http://labs.med.miami.edu/
myers/LFuN/LFuN.html). Further information and requests
for resources and reagents should be directed to the corres-
ponding author.
Results
APP and MAPT
It is possible that since both amyloid-b and tau proteins are
deposited in late-onset Alzheimer’s disease brains, they
might be difﬁcult to detect via tandem mass spectrometry
techniques because of inefﬁcient digestion; therefore, we
ﬁrst examined our data for known targets to make sure
that corresponding peptides could be detected. To increase
power, this analysis was performed across both series at
once (n = 320 late-onset Alzheimer’s disease, 338 pathology
free controls, 115 mild cognitive impairment). The
Consortium to Establish a Registry for Alzheimer’s
Disease (CERAD) (Mirra et al., 1991) and Braak (Braak
and Braak, 1995) staging were performed in each series.
One peptide mapping to amino acids 17–28 of the amyl-
oid-b peptide (LVFFAEDVGSNK, detected in 47% of the
series) and four tau peptides (HLSNVSSTGSIDMVDS
PQLATLADEVSASLAK, detected in 76% of the series;
HVPGGGSVQIVYKPVDLSK, detected in 96% of the
series; SGYSSPGSPGTPGSR, detected in 60% of the
series; and IGSLDNITHVPGGGNK, detected in 98% of
the series) were detected, thus demonstrating that our
protocol was able to detect known late-onset Alzheimer’s
disease peptides. These peptides were examined to see if
they were at increased levels in late-onset Alzheimer’s dis-
ease as would be expected based on the amyloid hypothesis
and our own work on microtubule associated protein tau
(Myers et al., 2005, 2007b). There were signiﬁcant in-
creases with the APP peptide and with two out of the
four tau peptides detected (APP_LVFFAEDVGSNK:
F = 33.23, P-value = 5.783  1014; MAPT_HVP
GGGSVQIVYKPVDLSK: F = 44.77, P-value5 2.2  1016;
MAPT_IGSLDNITHVPGGGNK: F = 90.137, P-value5 2.2
 1016; MAPT_HLSNVSSTGSIDMVDSPQLATLADEV
SASLAK: F = 0.4054, P-value = 0.667; MAPT_SGYSSPGS
PGTPGSR: F = 1.4254, P-value = 0.242).
Peptide proﬁles were also examined to determine consist-
ency with respect to late-onset Alzheimer’s disease pathology.
CERAD scores are a measure of neuritic plaque density cor-
rected for age [see Table 1 in Mirra et al. (1991)]. The series
mostly contains the oldest CERAD age group (age 475)
where CERAD scores reﬂect neuritic plaque density and
thus, this staging reﬂects amyloid-b levels. A consistent ele-
vation in levels of APP_LVFFAEDVGSNK peptide was seen
as CERAD scores progressed from 0 (no plaques) to C (mod-
erate to frequent plaques depending on the age bracket).
Braak staging quantiﬁes the amount and cortical distribution
of neuroﬁbrillary tangles. Neuroﬁbrillary tangles are com-
posed of paired helical ﬁlaments of hyper-phosphorylated
tau, and therefore, we hypothesized that as neuroﬁbrillary
tangle pathology was more widespread, tau peptides would
show increased expression. This occurred for two of the tau
peptides (MAPT_HVPGGGSVQIVYKPVDLSK and MAPT_
IGSLDNITHVPGGGNK), which were the same peptides that
were differentially expressed. Examining the alignment of
these two peptides within the MAPT gene, the two peptides
that were differentially expressed and correlated with Braak
staging (MAPT_HVPGGGSVQIVYKPVDLSK and MAPT_
IGSLDNITHVPGGGNK) aligned to the microtubule binding
repeat regions of MAPT, whereas the two peptides that were
not differentially expressed or correlated with Braak score
aligned just outside the binding repeat regions.
Thus, our peptide data captured the known key targets
involved in late-onset Alzheimer’s disease pathogenesis.
Peptides aligning to these targets were differentially distrib-
uted both with late-onset Alzheimer’s disease diagnosis and
post-mortem pathological measures. This ﬁnding gave us
further conﬁdence to proceed with an analysis of all data-
sets in both cohorts.
All targets
Differential expression
There were 8044 signiﬁcantly differentially expressed tran-
scripts in the KRONOSII set (Supplementary material:
Ancillary Dataset 1, Differentially Expressed Transcripts)
and 347 transcripts in the RUSH series (Supplementary
material: Ancillary Dataset 1, Differentially Expressed
Transcripts). These transcripts were used to seed the con-
struction of the network models. For the peptide data, there
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were 176 signiﬁcant differentially expressed peptides com-
paring late-onset Alzheimer’s disease and controls in the
KRONOSII data (Supplementary material: Ancillary
Dataset 2, Differentially Expressed Peptides) and 29 in
the RUSH series (Supplementary material: Ancillary
Dataset 2, Differentially Expressed Peptides). In comparing
mild cognitive impairment tissue proﬁles to pathologically
conﬁrmed controls, no signiﬁcant differences were
observed; therefore, mild cognitive impairment data were
only used to conﬁrm levels from key targets and not for
network construction.
Expression quantitative trait loci
We analysed allelic-transcript correlations and allelic-peptide
correlations; however, only allelic-transcript relationships
had signiﬁcant expression quantitative trait loci. This is
not surprising given that there is a direct relationship be-
tween DNA alleles and downstream RNA expression and
furthermore, the path between DNA alleles to peptide pro-
ﬁles is considerably more convoluted. Additionally, peptide
datasets are sparse, which can complicate analysis; therefore,
the analysis of peptide data in the context of allelic drivers
requires a more complex approach than standard protein
quantitative trait loci single target metrics. For our data,
peptides were incorporated at the multiscale network ana-
lysis level, which will allow for RNA to act as an intermedi-
ary signal (see the following section).
In a prior analysis (Webster et al., 2009), we found that
9% of transcripts we tested showed a genome-wide signiﬁ-
cant correlation with SNP genotype using a bootstrapping
procedure for correction. In our current datasets, for
KRONOSII 12% of transcript probes tested were signiﬁ-
cantly correlated with allele dosage in cis (5% FDR), and
for RUSH 18% of transcript probes tested were signiﬁcantly
correlated with allele dosage in cis (5% FDR). Of these cis
expression quantitative trait loci detected in each cohort, 1975
expression quantitative trait loci were overlapping between the
sets (Supplementary material: Ancillary Dataset 3, Cis
Overlapping expression quantitative trait loci), a 1.6-fold en-
richment over what would have been expected by chance
(Fisher’s exact P5 2.23  10191). Additionally, we replicated
50% of the cis expression quantitative trait loci detected in
our ﬁrst report (Webster et al., 2009), even though these stu-
dies comprised different sample sets and proﬁled using differ-
ent microarrays. We also detected 113 trans expression
quantitative trait loci in the KRONOSII set and 246 trans
expression quantitative trait loci in the RUSH set. Of the
trans expression quantitative trait loci identiﬁed, 40 were over-
lapping between the KRONOSII and RUSH sets, a 21-fold
enriched over what would be expected by chance (Fisher’s
exact P5 1016). All cis hits are mapped in Fig. 2A and B.
Networks
Multiscale co-expression network
Examining the multiscale aggregate transcript-peptide net-
works, most modules were either predominantly comprised
transcripts or peptides, demonstrating that these datasets are
quantitatively independent (Supplementary Fig. 2). This result
was not unexpected given previous correlation coefﬁcient es-
timates of 0.27 between gene and corresponding peptide ex-
pression traits (Ghazalpour et al., 2011). There are technical
differences in collecting oligonucleotide proﬁles versus amino
acid proﬁles, which may result in low levels of correlation.
There are also biological differences in the way that oligo-
nucleotides and amino acids are handled within a cell.
Cleavage, sorting, and the timing of degradation can all act
to vary amino acid proﬁles away from oligonucleotide pro-
ﬁles in biologically meaningful ways. APP represents a good
example of this effect in late-onset Alzheimer’s disease; tran-
script proﬁles are unchanged, but through differential cleav-
age, peptide proﬁles are altered. This further emphasizes the
importance of analysing both RNA and peptide. Since multi-
scale co-expression network analysis is rooted in correlations,
this method was not appropriate for discovery of connections
between transcripts and peptides. Thus, we developed causal
predictive networks, conditionally testing relationships and
facilitating the identiﬁcation of non-linear relationships be-
tween transcripts and peptides.
In these multiscale co-expression networks (transcript
plus protein), there were 26 modules in KRONOSII late-
onset Alzheimer’s disease and 32 modules in RUSH late-
onset Alzheimer’s disease (Supplementary material:
Ancillary Dataset 8, KRONOSII multiscale co-expression
networks; and Ancillary Dataset 9, RUSH multiscale co-
expression networks). For the control data, there were 25
and 32 modules for KRONOSII and RUSH, respectively
(Supplementary material: Ancillary Dataset 8, KRONOSII
multiscale co-expression networks; and Ancillary Dataset 9,
RUSH multiscale co-expression networks). Figure 3E–H
gives the functional enrichments for each module for the
aggregate multivariate co-expression network predictions.
The ﬁve most signiﬁcantly enriched biological processes
that replicated across the late-onset Alzheimer’s disease
KRONOSII and RUSH datasets were: (i) generation of pre-
cursor metabolites and energy; (ii) tissue development; (iii)
response to unfolded protein; (iv) defence response; and (v)
hydrogen peroxide catabolic process. In the control modules,
the four most enriched biological processes that replicated
across the KRONOSII and RUSH datasets were: (i) response
to virus; (ii) response to unfolded protein; (iii) regulation of
action potential in neuron; and (iv) RNA metabolic process.
While comparing the molecular signatures database and
gene ontology processes gives a general idea of the overlap
between KRONOSII and RUSH, this is not a direct com-
parison of module membership. Membership of all
KRONOSII late-onset Alzheimer’s disease modules was
compared to RUSH late-onset Alzheimer’s disease modules
and KRONOSII control modules to RUSH control modules
(Fig. 3I and J). In no case was there perfect overlap be-
tween KRONOSII and RUSH structure; however, there
were several modules that had some degree of overlap,
showing similarities between the two datasets.
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Multi-scale causal predictive network
There were six modules that were enriched for differentially
expressed genes in the KRONOSII set and ﬁve modules in
the RUSH set. The ﬁnal directed networks consisted of
1931 peptides and 2465 interactions for KRONOSII pep-
tides only network, and 1931 peptides and 2524 inter-
actions for RUSH peptides only network; 8153 genes and
10 848 interactions for KRONOSII transcript only net-
work, and 7357 genes and 9962 interactions for RUSH
transcript only network; 10 160 genes, 1931 peptides, and
14 103 interactions for KRONOSII multiscale network, and
9338 genes, 1931 peptides, and 13 478 interactions for
RUSH multiscale network.
Key driver analysis
The key driver results are shown in Fig. 4A and B. In total,
there were 100 transcripts appearing in at least two
networks and 105 peptides identiﬁed as key drivers. Of
these key drivers, 80 transcript key drivers and 53 peptide
key drivers were replicated between KRONOSII and
RUSH. We selected three transcript hits and four peptide
hits for experimental validation. Targets were prioritized
that were differentially expressed and/or if they were an
expression quantitative trait loci in the transcript dataset.
Data validation
Of the seven targets, one target (ST18) was not followed
due to construct size and cost. The other six constructs
were tested in the HEK293 and H4 lines. Of the other
targets, three (HSPA2, GNA12, COMT) were overex-
pressed in at least one late-onset Alzheimer’s disease
cohort, and two were under expressed in late-onset
Alzheimer’s disease (PDHB and RGS4) (Table 1). For
these constructs we replicated the late-onset Alzheimer’s
Figure 2 Cis expression quantitative trait loci. All cis expression quantitative trait loci hits are plotted for (A) KRONOSII and (B) RUSH.
Results from each chromosome (x-axis) are highlighted in a different colour. Each point denotes one cis SNP–probe relationship. Prior genome-
wide association studies and key driver hits are marked by dashed grey lines.
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Figure 3 Networks. Shown are the fraction of peptides mapping to their corresponding gene target in each module used in the analysis for the
(A) KRONOSII late-onset Alzheimer’s disease set, (B) Rush late-onset Alzheimer’s disease set, (C) KRONOSII Control set, and (D) RUSH
Control Set. Darker colours indicate all peptides for a given target mapped to both the same module as well as to the same gene target. As can be
seen on the figure, there is an imperfect correlation between module membership, gene mapping and peptide identity. Testing for whether
counts of peptides for a particular protein mapped to the same or different modules was significant in both the KRONOSII (Fisher’s exact
P-value = 0.0002, alpha = 0.05), and RUSH sets (Fisher’s exact P-value = 0.05, alpha = 0.05). In E–H, Gene ontology pathways are shown for
modules from multiscale co-expression predictions that are enriched for differentially expressed targets from the (E) KRONOSII late-onset
Alzheimer’s disease dataset, (F) RUSH late-onset Alzheimer’s disease dataset, (G) KRONOSII pathology-free dataset and (H) RUSH pathology-
free dataset. The x-axis plots each module and y-axis is the log10 P-value of the enrichment analysis. Modules and processes to the left of the line
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disease state, overexpressing HSPA2, GNA12, COMT and
knocking down PDHB and RGS4. CCT5 was not differ-
entially expressed, but was followed as a key driver pep-
tide. CCT5 was overexpressed as a ﬁrst pass of replication.
Our goal was to obtain consistent measures of changes of
amyloid-b and/or tau at multiple time points (48, 72 and
96 h) after transduction.
For RGS4, there was a signiﬁcant downregulation of
amyloid-b40 at all time points measured, but no effect on
amyloid-b42 (Supplementary Fig. 3E). This drop in amyloid-
b levels is counter to the effects seen in brain tissue. In the
brain tissue having less RGS4 was toxic and therefore, amyl-
oid-b should be increased with less RGS4. Alternatively, the
lower levels of RGS4 could be reﬂecting end-stage protective
compensatory mechanisms, and in that context the results
make sense. The amyloid-b results for PDHB were for the
most part non-signiﬁcant, with only one time-point showing
a difference in amyloid-b40 (Supplementary Fig. 4E). For tau,
there were no signiﬁcant results with RGS4 nor was there
any trend in the data (Supplementary Fig. 4E). For PDHB,
there was no change in total tau and p-tau was signiﬁcant at
two out of three time points measured (Supplementary Fig.
4E). These effects are consistent with the brain tissue data,
since there was less expression of PDHB in late-onset
Alzheimer’s disease brains therefore, tau should be increased
with knockdown.
Several of the key driver overexpressed targets (CCT5,
COMT and GNA12) signiﬁcantly changed either levels of
tau and p-tau (CCT5 and COMT) or amyloid-b40 and amyl-
oid-b42 (GNA12), but not both consistently (Supplementary
Figs 5–7). Most of these results matched to what would be
expected from the proﬁles in brain tissue, i.e. increases in the
canonical pathological proteins with target overexpression.
CCT5 was the exception and showed consistent decreases in
amyloid-b42, counter to the expected overexpression. It is
notable that there is less total RNA present with CCT5
transduction (Supplementary Fig. 5); thus, this effect may
be secondary to HEK cell death. Additionally, as with
RGS4, CCT5 overproduction could be protective and com-
pensatory to pathogenic processes. Finally, CCT5 is not sig-
niﬁcantly changed in terms of differential expression
(Supplementary Fig. 5A); therefore, more complex modelling
rather than just overexpression may be required.
Our best validated target from the key driver prediction
using the transcript dataset was HSPA2. This target signiﬁ-
cantly elevated amyloid-b40 and amyloid-b42 at all time
Figure 3 Continued
are replicated across sets. Colours are kept consistent to arbitrary assignments by Weighted Gene Co-expression Network Analysis. Processes
are as follows. (E) (KRONOSII AD): 1, Generation of precursor metabolites and energy; 2, Tissue development; 3, Response to unfolded protein;
4, Defence response; 5, Hydrogen peroxide catabolic process_1; 6, Hydrogen peroxide catabolic process_2; 7, Translational elongation; 8,
Gluconeogenesis; 9, Neurological system process; 10, Response to stress; 11, Glial cell differentiation; 12, Blood vessel development; 13, Cellular
catabolic process; 14, Respiratory electron transport chain_1; 15, Respiratory electron transport chain_2; 16, Axon guidance; 17, Response to
electrical stimulus; 18, Response to chemical stimulus; 19, Negative regulation of cellular biosynthesis; 20, DNA recombination; 21, Regulation of
microtubule-based process; 22, Ether metabolic process; 23, Negative regulation of transcription from RNA polymerase II promoter; 24,
Intracellular protein transmembrane import; 25, Telomere maintenance. (F) (RUSH AD): 1, Generation of precursor metabolites and energy; 2,
Tissue development; 3, Response to unfolded protein; 4, Defence response; 5, Hydrogen peroxide catabolic process_1; 6, Hydrogen peroxide
catabolic process_2; 7, Nuclear-transcribed mRNA catabolic process; 8,Type I interferon signalling pathway; 9, Cellular respiration_1; 10, Ion
transport; 11, Ensheathment of neurons; 12, Cellular respiration_2; 13, Protein polymerization; 14, Regulation of protein complex disassembly; 15,
Negative regulation of gene expression; 16, Cellular macromolecule metabolic process; 17, Neuron development; 18, Positive regulation of MAPK
cascade; 19, Microtubule bundle formation; 20, RNA Methylation; 21, Single-organism behaviour; 22, Carboxylic acid metabolic process; 23,
Glycosphingolipid metabolic process; 24, Regulation of mRNA catabolic process; 25, Cell volume homeostasis; 26, Oxidation-reduction process;
27, Mitotic Spindle assembly checkpoint 28, G2 DNA damage checkpoint; 29, Regulation of defence response to virus by virus; 30, RNA
processing; 31, Positive regulation of signalling. (G) (KRONOSII control): 1, Response to virus; 2, Response to unfolded protein; 3, Regulation of
action potential in neuron; 4, RNA metabolic process; 5, Organic substance catabolic process; 6, Regulation of immune system process; 7, Cellular
respiration; 8, Monosaccharide biosynthetic process; 9, Single-organism transport; 10, Extracellular matrix organization; 11, Generation of
precursor metabolites and energy; 12, Hydrogen transport; 13, Hydrogen peroxide catabolic process; 14, Single-multicellular organism process;
15, RNA splicing via transesterification reactions with bulged adenosine as nucleophile; 16, Protein dephosphorylation; 17, Synapse organization;
18, Retrograde vesicle-mediated transport Golgi to ER; 19, Negative regulation of cellular carbohydrate metabolic process; 20, Synaptic trans-
mission; 21, Amyloid precursor protein metabolic process; 22, Centrosome duplication; 23, Cellular response to growth factor stimulus; 24,
Cilium assembly. (H) (RUSH control): 1, Response to virus; 2, Response to unfolded protein; 3, Regulation of action potential in neuron; 4, RNA
metabolic process; 5, Defence response_2; 6, Cellular membrane organization; 7, Generation of precursor metabolites and energy_1; 8,
Generation of precursor metabolites and energy_3; 9, Translational termination; 10, Cellular response to zinc ion; 11, Ion transport; 12, Defence
response_1; 13, Protein folding; 14, Angiogenesis; 15, Skeletal muscle cell differentiation; 16, Proton transport; 17, Hydrogen peroxide metabolic
process; 18, Generation of precursor metabolites and energy_2; 19, Regulation of synaptic plasticity_2; 20, Glutamate receptor signalling pathway;
21, Peptidyl-glutamic acid modification; 22, Regulation of RNA metabolic process; 23, Androgen receptor signalling pathway; 24, Nuclear-
transcribed mRNA catabolic process exonucleoytic; 25, Synapse maturation,; 26, Regulation of synaptic plasticity_1; 27, Cerebral cortex de-
velopment; 28, Dephosphorylation; 29, RNA stabilization; 30, Phagocytosis; 31, Response to copper ion. (I and J) Heatmaps of the overlap
between KRONOSII and RUSH for the (I) late onset Alzheimer’s disease datasets and (J) control datasets. Again, seeding datasets and module
prediction were performed completely independently for each dataset; therefore, this is a true replication. As can be seen, many modules had low
overlap between sets; however, there were several modules where membership was highly overlapping (dark red) indicating that module
prediction can replicate from series to series.
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Figure 4 Key driver analysis. (A) Transcripts. Shown is the graph counting the significant over-representation of particular key drivers in the
networks using the transcript dataset as the projection series. Four separate networks were examined: (i) KRONOSII causal predictive transcript
network; (ii) RUSH causal predictive transcript network; (iii) KRONOSII causal predictive transcript and peptide network; and (iv) RUSH causal
predictive transcript and peptide network. The colour of the boxes represents which dataset the key driver originates from, and the shade
represents which seeding gene list it belongs to. There were six seeding gene lists used: (i) the intersection of each module transcripts with
differentially expressed transcripts from KRONOSII (KRONOS_DE_Gene_GenModule); (ii) the module transcripts from KRONOSII
(KRONOS_GeneModule); (iii) the full differentially expressed transcript set from KRONOSII (KRONOS_PURE_DE); (iv) the intersection of each
module transcripts with differentially expressed transcripts from RUSH (RUSH_DE_Gene_GenModule); (v) the module transcripts from RUSH
(RUSH_GeneModule); and (vi) the full differentially expressed transcript set from RUSH (RUSH_PURE_DE). The x-axis includes the top key
drivers, the y-axis counts the number of times the target is a key driver in any of the modules. Targets can be counted greater than four times if
they appear in multiple replicated modules. Green highlights TYROBP. (B) Peptides. Shown is the graph counting the significant over-representation
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points measured (Fig. 5B and E). Tau and p-tau were also
elevated, with every time point signiﬁcant except for the
ﬁrst collection of p-tau (Fig. 6C and D). Correcting for
cell densities, HSPA2 gave a 1.8-fold increase in patho-
logically processed amyloid-b40, a 1.6-fold increase in
amyloid-b42, a 2.2-fold increase in total tau and a 3.4-
fold increase in p-tau (Table 2). While these changes are
modest, given that in our cells amyloid-b and tau protein
are already overexpressed 20-fold and 5-fold, it is
encouraging that further consistent increases can be
obtained.
Discussion
Through our analysis of pathologically conﬁrmed brain tis-
sues, we have shown the following: (i) DNA–RNA–protein
networks are robust and replicable; (ii) protein proﬁling
uncovered novel key drivers and was crucial to understand-
ing data outputs; (iii) inclusion of mild cognitive impair-
ment subjects added modest value to the screen, since
there were no signiﬁcant differentially expressed genes;
(iv) having two distinct datasets was crucial, since not all
mapped processes replicated; (v) the defence response is a
major driver of late-onset Alzheimer’s disease differences,
which replicates prior ﬁndings (Zhang et al., 2013); (vi)
there are other replicated major processes beyond defence
response, indicating the potential for further hits; (vii) repli-
cated key drivers have downstream effects on the amyloid-b
and tau canonical pathways; and (viii) by examining each
target in isolation in systems that mimic late-onset
Alzheimer’s disease pathology, we have ﬁrmly demon-
strated that the effects we have reported are both speciﬁc
to late-onset Alzheimer’s disease and are not the result of
secondary declines due to technical artefacts, agonal state
or neurodegeneration in general. There are some limitations
to the work. First, while our sample sizes are appropriate
for ‘omics work given the hypothesis-free nature of net-
work analysis, our sample is smaller than most genome-
wide association studies screens. Second, given the nature
of brain tissue and the extensive data collection involved in
this work, there is the potential for noise additions at each
step. We accounted for this by performing replications with
two independent series and cell culture work on each single
target to validate effects, but it is still a possible factor.
Finally, much more extensive phenotyping needs to be
performed to determine the exact nature of the relation-
ships between targets and APP or tau response. The work
presented is an initial step of many to dissect the true
nature of this pathology.
Single target effects
Single targets were assessed using differential expression
and expression quantitative trait loci analysis. It is notable
that there was a considerable difference in differential ex-
pression outcomes whereby the RUSH cohort had fewer
differences. Since data were normalized at the same time,
using the same procedures, this is likely to not be quality
control variability. It is possible that this is because of the
differences in the nature of the collections. KRONOSII is
an extremely selected cohort, with little secondary path-
ology. This is not the case with RUSH where there is a
greater mixture of pathologies. We had signiﬁcant overlap
between sets for expression quantitative trait loci predic-
tions, both in the cis sets and in the trans set as well as
our original report.
Major network effects
There were ﬁve main processes that were signiﬁcantly en-
riched in the late-onset Alzheimer’s disease modules and
replicated across the KRONOSII and RUSH datasets: gen-
eration of precursor metabolites and energy, tissue develop-
ment, response to unfolded protein, defence response, and
hydrogen peroxide catabolic process. Generation of precur-
sor metabolites and energy are processes involved in the
mitochondrial electron transport chain or glycolysis. This
is consistent with existing data in that mitochondrial dys-
function in late-onset Alzheimer’s disease has been mapped
in many studies (Hong et al., 2008; Moreira et al., 2010).
Additionally, changing glycolytic pathways might change
susceptibility to amyloid-b late-onset Alzheimer’s disease
pathology (Fu et al., 2015) and cell mis-metabolism is
likely a general process in neurodegeneration (Ngo and
Steyn, 2015). Tissue development is a broad term with
30 subprocesses, including tissue regeneration as a sub-
class. This module likely reﬂects processes involved in tissue
repair and maintenance. The unfolded protein response
(UPR) is a mechanism for cells to compensate for accumu-
lation of unfolded proteins within the endoplasmic reticu-
lum. This response involves an upregulation of resident
Figure 4 Continued
of particular key drivers in the networks using the peptide dataset as the projection series. Four separate networks were examined: (i) KRONOSII
causal predictive peptide network; (ii) RUSH causal predictive peptide network; (iii) KRONOSII causal predictive transcript and peptide network;
and (iv) RUSH causal predictive transcript and peptide network. The colour of the boxes represents which dataset the key driver originates from
and the shade represents which seeding gene list it belongs to. There were four seeding gene lists used: (i) the full set of transcripts and peptides
from KRONOSII (KRONOS_multi); (ii) the entire peptide set from KRONOSII (KRONOS_protein); (iii) the full set of transcripts and peptides
from RUSH (RUSH_multi); and (iv) the entire peptide set from RUSH (RUSH_protein). The x-axis includes the top key drivers, the y-axis counts
the number of times the target is a key driver in any of the modules from the module enrichment set. Targets can be counted greater than two
times if they appear in multiple replicated modules.
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chaperone genes to facilitate folding. Speciﬁc to late-onset
Alzheimer’s disease, the UPR has been implicated in famil-
ial Alzheimer’s presenilin 1 (PSEN1) toxicity (Katayama
et al., 1999) as well as more generally in the earliest
stages of late-onset Alzheimer’s disease neuropathology
(Hoozemans et al., 2009). Our ﬁnding that defence re-
sponse is a replicated process is in line with our prior
report (Zhang et al., 2013), where TYROBP was mapped
as a major effect and generally immune and inﬂammatory
processes are overrepresented. TYROBP was a key driver
of effects in both series. Finally, both KRONOSII and
RUSH were enriched for targets that are involved in path-
ways resulting in the breakdown of hydrogen peroxide.
Due to high oxygen consumption, brain tissue generates
hydrogen peroxide along with other reactive oxygen spe-
cies. Amyloid-b can bind catalase and speciﬁcally inhibit
the breakdown of hydrogen peroxide (Milton, 1999) and
this may contribute to neuropathology.
Specific network targets
Of the selected targets, we obtained results for six of them:
one target from the transcript set, two from the peptide set
and three targets based on differential expression or eQTL
signiﬁcance. In the transcript key driver dataset, HSPA2
gave the most robust results through our pipelines. The
transcript was a key driver in both datasets, appearing
four times in the KRONOSII predictions and four times
in the RUSH predictions. It was also differentially ex-
pressed in the KRONOSII dataset. Examining HSPA2 in
the context of overexpressed amyloid-b and tau gave sig-
niﬁcant results in all cases; HSPA2 overexpression further
drove production including the more toxic amyloid-b42 and
p-tau subspecies.
HSPA2 is a member of the larger Hsp70 group of heat
shock protein genes. Heat shock proteins were ﬁrst identi-
ﬁed for their role in protein folding and the chaperone
system; however, further data now indicate a wider in-
volvement in a vast array of cell processes such as synaptic
transmission, autophagy, endoplasmic reticulum stress re-
sponse, protein kinase and cell death signalling (Stetler
et al., 2010). Hsp70 has been extensively studied in
Alzheimer’s disease and Down syndrome. Counter-intui-
tively, elevations in Hsp70 levels are thought to be neuro-
protective (Muchowski and Wacker, 2005; Leak, 2014);
however, to date, most of the studies have been focused
on the stress induced forms (Hsp70-A1 and Hsp70-A2),
which are encoded by the HSPA1A and HSPA1B genes
and not HSPA2 (Leak, 2014). In mammalian systems
there are 13 separate Hsp70 genes and HSPA2 encodes
the minor form of the constitutively active species of
Hsc70, with the major Hsc70 form being encoded by
HSPA8. Besides differences in activity and response, there
are differences in expression between Hsp70 and Hsc70
with Hsc70 being the major form in brain (Daugaard
et al., 2007). Thus, our ﬁnding that HSPA2 elevations act
to proliferate late-onset Alzheimer’s disease pathologyT
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might not be counter to the previous results, but instead
represent a separate related pathway.
Our ﬁnding that HSPA2 acts to speciﬁcally increase
levels of amyloid-b40, amyloid-b42, total tau and p-tau sug-
gests that changes in HSPA2 are not merely due to second-
ary or technical effects such as agonal state, but are speciﬁc
to late onset Alzheimer’s disease processes. Additionally,
performing an unbiased hypothesis-free screen was crucial
to detect HSPA2 since it is neither the most studied indu-
cible Hsp70 form, nor even the major component of the
constitutive form.
Interestingly, HSPA2 maps within a non-signiﬁcant link-
age peak found on chromosome 14 using a series of sibling
pairs collected from late-onset Alzheimer’s disease families
(Myers et al., 2002). HSPA2 was originally suggested as an
early-onset Alzheimer’s disease gene due to its location
close to markers thought to map near the AD3 locus
(Cruts et al., 1995) as well as its known signiﬁcant associ-
ation with Alzheimer’s disease pathology (Hamos et al.,
1991). After a reassessment of the linkage maps, the AD3
locus was eventually mapped as PSEN1 (Sherrington et al.,
1995). The late-onset Alzheimer’s disease chromosome 14
locus has yet to be mapped. It is notable that this is not a
signiﬁcant linkage peak, but it is intriguing that HSPA2
maps within the region.
RGS4 was under-expressed in late-onset Alzheimer’s dis-
ease and decreased amyloid-b40 at all time points, with no
effects on amyloid-b42, tau and p-tau; thus, it was one of the
weakest of all of our validations. RGS proteins activate GTP
hydrolysis by the alpha subunit of heterotrimeric G proteins
and by this means inhibit G-protein coupled receptor
(GPCR) signalling. RGS4 has been associated with the de-
velopment of schizophrenia (Chowdari et al., 2002). GPCR
signalling is generally implicated in amyloid-b processing
(Thathiah et al., 2009) and targeting GPCRs has been sug-
gested as a possible therapeutic pathway; however, Rgs4
knockout mice did not have any deﬁcits in associative learn-
ing or working memory (Grillet et al., 2005), so it may be
that knockdown of RGS4 is not the best GPCR pathway
target and GNA12 may be a more viable alternative.
Figure 5 HSPA2 APP measures. (A) Shows the level of transcript expression for HSPA2 for the two detected probes in both KRONOSII
(top) and RUSH (bottom). Only KRONOSII showed significant differential expression. The levels of total RNA (C, 96 h shown, measured as a
surrogate of the level of cell death), transcript overexpression both for target and APP (D, 96 h shown, boxplot of three replicates), amyloid-b40
peptide levels (B) and amyloid-b42 peptide levels (E) for three repeat measures of conditioned media at three different time points of the top key
driver target in the HEK293sw cell line are plotted. Measurements are taken at 48, 72 and 96 h post transduction. Control = measurements from
cells transduced with an empty vector; HSPA2 = measurements from cells transduced with target. + limma P-value; *t-test P-value.
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In the peptide dataset, CCT5 was counted in two
KRONOSII modules and COMT was counted in ﬁve
RUSH modules. Both of these targets signiﬁcantly elevated
tau and p-tau at most time points; however, for COMT
there was no effect on amyloid-b40 or amyloid-b42 levels.
CCT5 only had a signiﬁcant effect on amyloid-b42 in that
there were decreased levels of amyloid-b42 released at mul-
tiple time points, but it is possible this change is a second-
ary effect due to cell death, since total RNA levels were
decreased over the course of the experiment.
CCT5 is a member of the same chaperonin complex as
HSPA2 (Neef et al., 2014). Speciﬁcally, CCT5 is a member
of the TCP1 complex, also known as TRiC. This complex
folds various proteins including actin (Gao et al., 1992)
and tubulin (Yaffe et al., 1992). Hsp70 co-puriﬁes with
CCT and it’s possible that they directly interact (Lewis
et al., 1992; Kubota et al., 1994); however, it is unclear
whether those results are speciﬁc to the forms we have
mapped.
COMT is the major catecholamine degrading enzyme,
acting in neurons and microglia after uptake from the syn-
aptic cleft. It was originally mapped as a gene of interest
for schizophrenia (Mier et al., 2010). There have been some
studies of COMT variation and Alzheimer’s disease risk;
Figure 6 HSPA2 tau measures. Shown in the figure are the levels of total RNA (A, 96 h shown, measured as a surrogate of the level of cell
death), transcript overexpression both for target and MAPT (C, 96 h shown, boxplot of three replicates), total tau peptide levels (B) and p-tau
peptide levels (D) for three repeat measures of conditioned media at three different time points of the top key driver target in the H4–4R0N cell
line. Measurements are taken at 48, 72 and 96 h post transduction. Control = measurements from cells transduced with an empty vector;
HSPA2 = measurements from cells transduced with target. *t-test P-value.
Table 2 HSPA2 fold-change
Cell line Peptide Empty vector HSPA2 OE Fold
change
HEK293sw Amyloid-b40, pg/ml 30 656 54 523 1.8
Amyloid-b42, pg/ml 4826 7533 1.6
H4–4R0N Tau[Total], pg/ml 10 190 22 055 2.2
Tau[pT181], pg/ml 1141 3918 3.4
Fold-change calculations for HSPA2 in the HEK293sw line and H4–4R0N lines. OE = overexpression.
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however, none of the large genome-wide association studies
meta-analyses (Lambert et al., 2013) have replicated
COMT as a gene for late-onset Alzheimer’s disease. Our
own work did not show a direct relationship between DNA
alleles and COMT mRNA or peptide expression.
In our cohorts, COMT was seen to be overexpressed in
late-onset Alzheimer’s disease brains, which would be con-
sistent with ﬁndings of reduced dopamine in Alzheimer’s
brain tissues (Storga et al., 1996). COMT overexpression
increased levels of tau and p-tau, but not amyloid-b. This
result appears to be at odds with the known synergies be-
tween tau and COMT. Activation of dopamine D1 recep-
tors causes protein kinase A (PKA) activation and results in
a downstream chain of events leading to tau hyperpho-
sphorylation (Lebel et al., 2009); therefore, higher levels
of synaptic dopamine and lower COMT activity in late-
onset Alzheimer’s disease would be expected. However,
imaging data have shown that low dopamine tone is asso-
ciated with an upregulation of binding at D1 receptors
(Guo et al., 2003), and the higher activity Val allele (similar
to an increase in COMT expression) shows increases in D1
receptor binding (Slifstein et al., 2008). Thus, our results
would indicate a model whereby there is mis-regulation of
the dopamine-COMT systems and insufﬁcient brain com-
pensatory mechanisms result in tau changes.
Two targets were followed because they were expression
quantitative trait loci in both sets and differentially ex-
pressed in KRONOSII. GNA12 was upregulated in late-
onset Alzheimer’s disease and PDHB was downregulated
in late-onset Alzheimer’s disease in the KRONOSII data.
Like RGS4, GNA12 is a part of the GPCR system. It is a
member of the alpha class of heterotrimeric G proteins,
which typically upon exchange of GDP to GTP, activates
downstream intercellular signalling pathways. GNA12
along with GNA13 represents a fourth class of alpha sub-
units (Strathmann and Simon, 1991). GNA12 can regulate
actin cytoskeleton remodelling and along with its GPCR
partners is a known activator of Rho (Riobo and
Manning, 2005). Upstream coupling can occur through
direct interactions with Rho guanine nucleotide exchange
factors (RhoGEFs) (Hart et al., 1998), ARHGEF11
(Jackson et al., 2001), cell adhesion molecules (Meigs
et al., 2001) and other effectors. HSP90 was shown to
directly bind GNA12 (Vaiskunaite et al., 2001), thus impli-
cating GNA12 in heat shock protein signalling. Hsc70 and
Hsp90 have shown to demonstrate cooperative binding in
other systems (Rajapandi et al., 2000; Iwasaki et al., 2010)
and are linked together through Hsp70-Hsp90 organizing
protein (Hop) (Johnson et al., 1998). It has also been
shown that the N-terminus of GNA12 contains a mito-
chondrial targeting sequence and is involved in the regula-
tion of mitochondrial motility, morphology and membrane
permeability (Andreeva et al., 2008).
GPCRs are known to affect APP processing via actions
on cleavage enzymes. Through direct coupling to beta and
gamma secretase, GPR3 has been shown to potentiate
gamma secretase APP cleavage in a screen for modulators
of amyloid-b production (Thathiah et al., 2009). GPR3 as-
sociates with the G(s) G protein subunit; therefore, it is
unlikely that there is a direct interaction between GNA12
and GPR3. It remains to be seen whether there is a direct
interaction between APP processing enzymes and GNA12,
as with GPR3, but our data suggest there is some modiﬁ-
cation of APP processing by GNA12.
PDHB is a part of the PDH complex, which is a nuclear-
encoded mitochondrial multi-enzyme complex that cata-
lyses the overall conversion of pyruvate to acetyl-CoA
and carbon dioxide and provides the primary link between
glycolysis and the tricarboxylic acid (TCA) cycle.
Mitochondrial dysfunction has been repeatedly mapped to
late-onset Alzheimer’s disease, and some studies have re-
ported oxidative damage preceding plaque formation, indi-
cating putative causation (Nunomura et al., 2001).
Knockdown of PDHB increased levels of p-tau in our
validation cell lines, but had no effect on total tau. PDH
has been shown to directly bind GSK3B, which results in
PDH phosphorylation and lowers PH activity. GSK3B also
phosphorylates tau, thus the link between PDHB and tau
effects in our data is probably via GSK3B (Hoshi et al.,
1996). In primary rat hippocampal culture, amyloid-b ex-
posure inactivated PDH and resulted in mitochondrial dys-
function, lowered acetylcholine levels in cholinergic
neurons and neuronal cell death (Hoshi et al., 1996); there-
fore, amyloid-b could be upstream of PDHB, which would
explain why we see no changes in amyloid-b. Our human
data ﬁt in nicely with effects mapped in animal models and
through our analysis we can speciﬁcally target the toxic
sub-component of PDH.
In summary, this study has mapped and validated six
novel targets via a hypothesis-free approach to uncovering
misregulation in DNA, RNA and protein relationships in
late-onset Alzheimer’s disease. Many of these targets repli-
cated between two distinct neuropathological datasets that
were collected in different manners (convenience and epi-
demiological) from different sources. Nominated targets
had some effect on amyloid-b40, amyloid-b42, tau or p-tau
in separate experiments using two different cell lines and
individual transduction of each target, demonstrating both
speciﬁcity to known late-onset Alzheimer’s disease path-
ways as well as causality. It is notable that our selection
pipeline was hypothesis-free; therefore, we did not enrich
for hits that would yield positive results, and indeed some
targets like RGS4 were not as consistent in our assays.
While our main targets mapped to pathways already impli-
cated in late-onset Alzheimer’s disease including the chap-
eronin complex, mitochondrial changes or the GPCR
signalling pathway, many of our targets have not been
studied in the context of late-onset Alzheimer’s disease.
Of all of our effects, HSPA2 gave the most consistent re-
sults in that this target was a key driver in both datasets,
differentially expressed and had the largest effects on levels
of amyloid-b and tau in already overexpressed model
systems.
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